Home » Stocks » ATXI

Avenue Therapeutics, Inc. (ATXI)

Stock Price: $6.62 USD 0.33 (5.25%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 110.37M
Revenue (ttm) n/a
Net Income (ttm) -9.57M
Shares Out 16.52M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE 17.99
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $6.62
Previous Close $6.29
Change ($) 0.33
Change (%) 5.25%
Day's Open 6.29
Day's Range 6.24 - 6.79
Day's Volume 259,437
52-Week Range 2.95 - 12.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today anno...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today anno...

PRNewsWire - 3 months ago

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics, Inc. ("Avenue Therapeutics" or the "Company") (NASDAQ: ATXI). Such ...

Zacks Investment Research - 3 months ago

Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.

Benzinga - 3 months ago

Shares of micro-cap biopharma Avenue Therapeutics Inc (NASDAQ: ATXI) are plummeting on above-average volume after a binary event panned out against the company. What Happened: New York-based A...

GlobeNewsWire - 3 months ago

Management to Host Conference Call at 8:30 a.m. ET Management to Host Conference Call at 8:30 a.m. ET

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, tod...

Zacks Investment Research - 5 months ago

Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, toda...

Zacks Investment Research - 5 months ago

Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.

Zacks Investment Research - 5 months ago

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.

Zacks Investment Research - 6 months ago

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.

GlobeNewsWire - 6 months ago

Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints Publication highlig...

Zacks Investment Research - 6 months ago

Is (ATXI) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Avenue Therapeutics

Zacks Investment Research - 7 months ago

Is (ATXI) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Other stocks mentioned: BJ, FRO, ICLK, PRQR
Zacks Investment Research - 7 months ago

Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.

Other stocks mentioned: CALX, ECOM, MGIC
GlobeNewsWire - 7 months ago

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, toda...

Zacks Investment Research - 7 months ago

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Other stocks mentioned: CNCE, MEIP, NERV, OCUL
Zacks Investment Research - 7 months ago

Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Other stocks mentioned: AAWW, BJ, HEAR, VERI
GlobeNewsWire - 8 months ago

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...

Zacks Investment Research - 8 months ago

Tech rally is here to stay on solid fundamentals. Bet on stocks that are yet to reclaim their 52-week high levels despite the recent uptrend.

Other stocks mentioned: BL, INSG, MTSI, WK, XLK
Zacks Investment Research - 8 months ago

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th

Other stocks mentioned: CANF, GFI, MN
Zacks Investment Research - 9 months ago

Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

Other stocks mentioned: CUE, GAIA, PJT, SPTN
Zacks Investment Research - 9 months ago

Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 9 months ago

Avenue Therapeutics Update: Shares A Steal Ahead Of Known PDUFA Action Date

GlobeNewsWire - 11 months ago

NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, toda...

Seeking Alpha - 1 year ago

Avenue Therapeutics Submits Its NDA; Shares Still Cheap

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, toda...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, anno...

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, toda...

Seeking Alpha - 1 year ago

Shares of Avenue Therapeutics have done virtually nothing over the last four months.

Seeking Alpha - 1 year ago

Avenue Therapeutics, Inc. (ATXI) CEO Dr.

Benzinga - 1 year ago

Avenue Therapeutics (NASDAQ: ATXI)'s second Phase 3 trial of IV tramadol for the treatment of postoperative pain following abdominoplasty is a success.

About ATXI

Avenue Therapeutics, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.

Industry
Biotechnology
IPO Date
Jun 27, 2017
Stock Exchange
NASDAQ
Ticker Symbol
ATXI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ATXI stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 35.95% from the latest price.

Price Target
$9.00
(35.95% upside)
Analyst Consensus: Buy